IM Cannabis Corp., a leading medical cannabis company operating in Israel and Germany, has strengthened its board of directors with the appointment of Shmulik Arbel. Arbel brings a wealth of experience in strategic plans that drive profitability, finance, and corporate governance, further solidifying the company’s commitment to growth and sustainable profitability.
Arbel, who retired as Deputy CEO from Leumi, Israel’s largest banking group, in April 2023, was instrumental in business growth and leading the service revolution at Leumi. With over 25 years of experience at the bank, Arbel has held senior roles, including head of retail banking, head of the corporate division, and chairman of Leumi UK. This extensive international experience, with key roles in Israel, New York, and London, provides him with a broad understanding of international business.
“We are thrilled to welcome Shmulik to our Board of Directors,” said Oren Shuster, Chief Executive Officer of IM Cannabis. “Shmulik’s extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives.”
Arbel expressed his excitement about joining the board, stating, “I am honored to join the Board of Directors at IMCC. I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company’s growth.”
Arbel holds a BA and MBA from Tel Aviv University.
IM Cannabis Corp. is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The company has focused its resources on achieving sustainable and profitable growth in its highest-value markets. They leverage a transnational ecosystem powered by a data-driven approach and a globally sourced product supply chain. With a commitment to responsible growth and compliance, IM Cannabis strives to become a global high-quality cannabis player.
In Israel, the company operates through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. IM Cannabis also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel to ensure the safe delivery and quality control of its products throughout the value chain.
In Germany, the company operates through Adjupharm GmbH, distributing cannabis to pharmacies for medical cannabis patients.
With Arbel’s addition to the board, IM Cannabis is poised to continue its expansion and solidify its position as a leading force in the global medical cannabis industry.
